MXCT (MaxCyte) ROCE %: -13.28% (As of Mar. 2026)

What is MaxCyte ROCE %?

MaxCyte MXCT +3.54% 62 ROCE % is -13.28% as of Mar. 2026. GuruFocus rates MXCT with a GF Score™ of 62/100 and a GF Value™ of $2.57 (Possible Value Trap). The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. MaxCyte's annualized ROCE % for the quarter that ended in Mar. 2026 was -13.28%.

MaxCyte (NAS:MXCT) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

MaxCyte ROCE % Related Terms

MaxCyte ROCE % Historical Data

* Premium members only.

The historical data trend for MaxCyte's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MaxCyte ROCE % Chart

MaxCyte Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

-11.69

-10.14

-18.52

-21.60

-21.99

MaxCyte Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															-22.31	-26.75	-21.88	-15.92	-13.28

62GF Score

MaxCyte Inc MXCT

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

MaxCyte ROCE % Calculation

MaxCyte's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	-45.285	/	( ( (239.47 - 15.775)	+	(202.507 - 14.267) )	/ 2 )
	=	-45.285	/	( (223.695	+	188.24)	/ 2 )
	=	-45.285	/	205.9675
	=	-21.99 %

MaxCyte's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	-24.74	/	( ( (202.507 - 14.267)	+	(194.473 - 10.212) )	/ 2 )
	=	-24.74	/	( ( 188.24	+	184.261 )	/ 2 )
	=	-24.74	/	186.2505
	=	-13.28 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of -13.28% mean?

MaxCyte (MXCT) has a ROCE % of -13.28% as of Mar. 2026.

Is MaxCyte's ROCE % too high?

MaxCyte's current ROCE % is -13.28%. Overall, MaxCyte has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does MaxCyte's ROCE % compare to RCEL and NNOX?

MaxCyte's ROCE % of -13.28% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Medical Devices & Instruments company?

The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MaxCyte's current ROCE % is -13.28%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is MaxCyte stock overvalued right now?

Based on GuruFocus' analysis, MaxCyte (MXCT) is currently considered Possible Value Trap. The stock's GF Value™ is $2.57, compared to a current price of $1.32 — trading 48.8% below its estimated fair value. The current ROCE % is -13.28%. MaxCyte's overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For MaxCyte (MXCT), the current ROCE % is -13.28% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MaxCyte (MXCT) Overvalued in 2026?

Based on GuruFocus' analysis, MaxCyte stock appears to be undervalued. The current stock price of $1.32 is trading 48.8% below its estimated GF Value™ of $2.57. GuruFocus considers MaxCyte to be Possible Value Trap.

Key valuation signals for MXCT:

ROCE %: -13.28%
GF Value™: $2.57 vs. price of $1.32 (48.8% below fair value)
GF Score™: 62/100 with 5 warning signs

No single metric tells the full story. See the MXCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

MaxCyte Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies RCEL NNOX SNWV QTRX CVRX STIM HYPR ZOMDF RPID OWLT ABT SYK MDT BSX EW XTER:SHL DXCM GEHC SZSE:300760 XAMS:PHIA

Other Exchanges MYE0:Germany

Address 9713 Key West Avenue, Suite 400, Rockville, MD, USA, 20850

Website https://www.maxcyte.com

MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.

62GF Score

Get the complete analysis for MXCT

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.32

Price

$2.57

GF Value

View MXCT Analysis

See ROCE % data for all stocks →